- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Epsiode 12 - Healthcare Reform's Impact on Immunotherapy (Part 1)
The Supreme Court’s approval of the Affordable Care Act leads the panelists into a discussion about how healthcare reform will affect the coverage of treatment modalities such as immunotherapy.
Although it remains unclear how the new system will affect cancer care, Daniel George, MD, believes that patients will benefit.
Jeffrey Weber, MD, PhD, explains that under “Obamacare” fewer patients will be uninsured. As a result, practitioners will be able to see and treat more patients.
The panelists agree that under the new system professionals will be able to treat patients with immunotherapy because patients will now have coverage to receive treatment. Before, immunotherapy was not always an option.
Additionally, Dr Weber explains that healthcare reform should not affect smaller practices any differently from larger practices. However, the panelists agree that it will be necessary under the new care system that any issues of wasteful spending be addressed, as this is currently extremely common.
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
